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Purpose: The purpose of this study was to assess the ability of quantitative in vivo confocal microscopy to characterize
the natural history and detect changes in crystal volume in corneas from a novel animal model of cystinosis, the cystinosin
(Ctns-/-) mouse.
Methods: Two Ctns−/− mice and one C57Bl/6 mouse were examined at each of the following time points: 2, 3, 5, 7, 10,
12, and 14 months of age. In vivo confocal microscopy scans were performed in 4 different regions of the cornea per eye.
After, animals were sacrificed and cornea blocks evaluated for cell morphology using phalloidin and lymphocytic
infiltration using CD45 antibodies by ex vivo confocal microscopy. Cystine crystal content in the cornea was measured
by calculating the pixel intensity of the crystals divided by the stromal volume using Metamorph Image Processing
Software.
Results: Corneal crystals were identified in Ctns−/− eyes beginning at 3 months of age and increased in density until 7–
12 months, at which time animals begin to succumb to the disease and corneas become scarred and neovascularized. Older
Ctns−/− mice (7 months and older) showed the presence of cell infiltrates that stained positively for CD45 associated with
progressive keratocyte disruption. Finally, at 12 months of age, decreased cell density and endothelial distortion were
detected.
Conclusions: Confocal microscopy identified corneal crystals starting at 3 month old Ctns−/− eyes. Cystine crystals induce
inflammatory and immune response with aging associated with loss of keratocyte and endothelial cells. These findings
suggest that the Ctns−/− mouse can be used as a model for developing and evaluating potential alternative therapies for
corneal cystinosis.
Cystinosis is an autosomal recessive lysosomal storage
disease that is characterized by the accumulation of cystine
crystals in various tissues, including the kidney, brain and eye
[1-4].  The  disease  has  been  linked  to  mutations  in  the
cystinosin (CTNS) gene (17p13) that codes for cystinosin, a
trans-membrane protein responsible for the transport of the
disulfide  cystine  amino  acid  out  of  the  lysosome  [5-9].
Different CTNS mutations are associated with a spectrum of
clinical disease, with patients categorized into one of three
severity groups based on their age at onset and symptoms
[10]. The infantile onset of the most severe form of the disease,
nephropathic cystinosis, results from the complete lack of
cystine transport, with onset of renal failure by age 10 [11,
12]. Corneal cystine crystals appear within the first 16 months
of life, increasing linearly during the first decade, until they
plateau in early adolescence [13-16]. The non-nephropathic
forms  of  cystinosis  (juvenile  and  ocular  cystinosis)
demonstrate some residual membrane transport function and
are associated with later onset and more limited systemic
manifestations. However, corneal crystals are also present in
these less severe forms of the disease [17].
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Oral administration of cysteamine (HS-CH2-CH2-NH3)
or β-mercaptoethylamine has been the mainstay of cystinosis
therapy  since  1994,  when  CYSTAGON®  (cysteamine
bitartrate, Mylan Pharmaceuticals Inc., Canonsburg, PA) was
approved by the USA FDA. A free thiol, cysteamine reacts
with cystine to produce the single sulfide amino acid cysteine,
plus  a  cysteine-cysteamine  mixed  disulfide  that  exits  the
lysosome via the lysine transporter. By circumventing the
transporter defect, oral cysteamine has significantly improved
overall prognosis [12,18-20]. However, no improvements in
ocular manifestations of the disease have been demonstrated
with  systemic  treatment,  presumably  due  to  the  lack  of
bioavailability of the drug in the cornea [11,21-23].
Cysteamine can be applied directly to the cornea via eye
drops and is effective in reducing corneal crystals. However,
the hourly dosing regimen that this medication requires is
impractical  for  effective  compliance  [24].  Progressive
photophobia,  recurrent  corneal  erosions,  foreign  body
sensation and visual deterioration associated with increasing
concentrations of corneal crystals have therefore become a
major  long-term  burden  for  patients  having  all  forms  of
cystinosis [14,25,26].
The low levels of intracorneal cysteamine achieved via
topical application are thought to result from poor compliance,
limited corneal penetration and drug instability [15,21,22,
27-31]. Development of alternative treatments for corneal
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2212disease has been hampered by the need for costly and time
consuming human clinical trials in this low prevalence disease
[20,32,33].  Further,  the  lack  of  an  objective,  quantitative
methodology to assess corneal treatment efficacy has forced
studies to rely on subjective patient complaints and semi-
quantitative slit-lamp biomicroscopy grading.
Recently, a cystinosis (Ctns−/−) knockout mouse has been
shown  to  develop  cystine  crystals  in  multiple  tissues,
including the cornea [34,35]. The ocular findings in the Ctns
−/−  mouse  have  been  further  characterized  using  slit  lamp
photography, assays of cystine levels in various ocular tissues,
and standard histology. Cystine crystals were identified in the
cornea as early as three months of age, while ocular tissue
levels  increased  dramatically  up  to  approximately  9–13
months. Most animals died between 13 and 20 months, with
corneal  vascularization  identified  histologically  in  older
animals. Importantly, corneal cystine crystals were located
within  keratocytes  throughout  the  stroma,  but  not  in  the
epithelium, Bowman’s membrane, Descemet’s membrane or
endothelium at any age [36].
The  corneal  findings  in  this  murine  knockout  model
appear to mimic disease progression in humans, where rapid
linear increases in corneal crystals have been noted between
birth and 6 years of age, with a plateau reached in the mid
teenage  years.  Subsequent  in  vivo  confocal  microscopy
studies in human nephropathic cystinosis patients 8–20 years
old have demonstrated needle shaped hyperreflective bodies
in the corneal epithelium and stroma of all patients [37-41].
In  this  study,  we  evaluated  a  quantitative  method  of
confocal microscopy to characterize the natural history and
localization of corneal crystal accumulation in the Ctns−/−
mouse model. This further development of the Ctns−/− mouse
model may enable more rapid and cost-effective screening of
potential alternative therapies for corneal cystinosis.
METHODS
Mice: A total of seven C57Bl/6 (normal control) mice and 14
Ctns−/− knockout mice were used in this study. Two Ctns−/−
mice and one C57Bl/6 mouse were examined at each the
following periods: 2, 3, 5, 7, 10, 12 and 14 months of age. This
timeframe was developed from initial studies that showed
most animals surviving to about 12 months, by which time
severe ocular changes, including phthisis bulbi began to be
noted.
At  each  time  point,  the  selected  animals  were
anesthetized with intraperitoneal injections of ketamine HCl
(100 mg/Kg bodyweight; Bioniche Pharma, Lake Forest, IL)
and xylazine (20 mg/Kg bodyweight; Lloyd Laboratories,
Shenandoah, IO). Clinical abnormalities were then detected
using  slit  lamp  biomicroscopy  and  in  vivo  confocal
microscopy  (CM)  to  assess  the  presence  and  location  of
cystine crystals. Animals were then sacrificed by cervical
dislocation under anesthesia, after which ex vivo evaluations
were performed. All procedures were approved by the UCI
IACUC and conducted in accordance with ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research.
Slit  lamp  photography:  Selected  eyes  were  photographed
using  a  Nikon  D200  digital  camera  (Nikon  Corporation,
Tokyo,  Japan)  attached  to  a  Nikon  NS-1  slit  lamp
biomicroscope (Nikon Corporation), to identify the presence
of crystals or abnormalities in the cornea.
In vivo confocal microscopy: Animals underwent in vivo CM
scanning  using  a  tandem  scanning  confocal  microscope
(TSCM; Tandem Scanning Corporation, Reston, VA) with a
24×  surface-contact  objective  (numerical  aperture,  0.6;
working distance, 1.5 mm), encoder mike controller (Oriel
18011; Oriel, Stratford, CT) for focal plane control, and a
camera (MTI VE-1000; Dage MTI, Michigan City, IN). One
drop of preservative-free, Refresh Tears (Allergan, Irvine,
CA) was placed on the tip of the objective as a coupling gel.
All  camera  settings  were  kept  constant  throughout  the
experiment. For each eye, repeated data sets were obtained
from select central and peripheral cornea locations. Three to
five  through-focus  data  sets  were  collected  around  these
regions  for  assessment  of  cystine  crystal  volume  using
Metamorph  Image  Analysis  software  (Molecular  Devices,
Downingtown, PA).
Ex vivo confocal microscopy: The eyes of sacrificed animals
were  enucleated  and  placed  in  2%  paraformaldehyde,
phosphate buffered saline, pH 7.4, for 10 min, after which
corneas were removed and fixed overnight. Tissue blocks
(2×2 mm) were then obtained and stained en bloc overnight
at 4 °C with nucleic acid stain (DAPI; Molecular Probes,
Eugene,  OR)  to  identify  nuclei,  phalloidin  (Alexa  Fluor
Rhodamine phalloidin; Invitrogen, Carlsbad, CA) to identify
cell  cytoskeleton  and  CD45  anti-mouse  FITC  conjugated
antibody (Abcam, Cambridge, MA) to identify inflammatory
cell infiltration.
Samples were placed on a microscope (Axiovert 200;
Zeiss,  Jena,  Germany)  and  imaged  with  a  laser  confocal
microscope system (LSM 510 META; Zeiss) equipped with
a  mode-locked  titanium/sapphire  laser  (Chameleon;
Coherent, Santa Clara, CA). The fluorescent signal detection
from  CD45,  rhodamine  phalloidin,  and  nucleic  acid  stain
(DAPI) was obtained using the 488-nm, 543-nm and 740-nm
laser  lines  of  the  argon,  and  helium-neon,  and  infrared/
femtosecond lasers.
Quantitative  assessment  of  cystine  crystal  content:  To
measure the cystine crystal content in the cornea, through
focus image data sets were analyzed by Metamorph Image
Processing Software (Molecular Devices, Downington, PA).
Initially, the stromal regions were extracted from the through
focus  data  set  and  then  thresholded  using  the  Threshold
subroutine to include all high intensity pixels representing
light scattering from the cystine crystals. Threshold regions
were set to include pixels intensity from 100 to 255. Pixels
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“Measure” subroutine for all planes in the image stack to
record the crystal volume. To calculate a “Percent Crystal
Volume  Index,”  the  crystal  volume  was  divided  by  the
extracted stromal volume.
Statistical analysis: Each eye was considered independently
and results are reported as the mean±standard deviation (SD).
Differences between age groups were evaluated statistically
using GraphPad Prism™ 3.0 (GraphPad Software Inc., San
Diego, CA), considering one-way Anova and Newman-Keuls
Multiple Comparison tests.
RESULTS
Slit lamp photography: Small hyper-reflective needle-shaped
deposits were first detected by biomicroscopy in the corneas
of Ctns−/− mice at 5 month of age, with more abundant crystals
at 7 months (Figure 1A). Three eyes of the 14 Ctns−/− animals
developed phthisis bulbi, with central corneal opacification,
loss of the normal ocular architecture and decreased ocular
size at ages 7, 12, and 14 months (Figure 1B).
In vivo confocal microscopy: Using in vivo CM, no corneal
cystine crystals were noted in any of the C57Bl/6 control mice
at  any  time  point.  In  the  Ctns−/−  mice,  cystine  crystals
(identified as small, highly reflective needle shaped deposits)
were first detected in the cornea at 3 months of age, located
both centrally and peripherally in the posterior cornea near the
endothelium (Figure 2A). By seven months of age, Ctns−/−
mice  developed  more  abundant  and  larger  needle  shaped
crystals in the mid posterior stroma, again noted in both the
central and peripheral cornea (Figure 2B). At 10 month of age,
crystals appeared thicker, shorter and were also noted in the
anterior stroma (Figure 2C). By 12 month of age, deposits
appeared more punctate with markedly fewer needle shaped
crystals (Figure 2D). Overall, these morphological changes
suggest that crystals increase in quantity until 7 month of age,
after which they begin to form aggregates, without significant
increase in crystal quantity.
Measurement  of  cystine  crystal  content:  To  quantify  the
progression of cystine crystal deposits in the cornea, we first
segmented the crystal volume from the 3-D in vivo CM scan
by thresholding the images to contain just the crystal volume.
The  data  set  was  then  volume  rendered  to  show  the  3-D
distribution of crystals within the mouse cornea (Figure 3). 3-
D renderings of the crystals were then used to calculate the
crystal volume in each cornea, and the volume recorded as the
percent  of  total  stromal  volume.  Quantitation  of  crystal
volume showed that at 2 months of age, no crystals were
detected in any Ctns−/− mice, however a small number of
crystals were detected by 3 months of age. Crystal volume
significantly increased 15-fold from 3 to 4 month of age and
fourfold from 4 to 7 month of age (p<0.05) or 56 fold overall.
From 7 to 10 month of age, there was a significant decrease
in crystal volume to half that detected at 7 months. There was
no significant change in crystal volume between 10 and 12
months of age (Figure 4).
Ex vivo confocal microscopy: To evaluate changes to the
keratocyte  population  associated  with  the  deposition  of
cystine crystals, we stained corneas for actin to identify cell
borders and DAPI to detect nuclei. Keratocytes in both the
C57Bl/6  and  2–3  month  old  Ctns−/−  mice  showed  typical
dendritic morphology and cortical actin staining (Figure 5A).
Actin  stained  corneas  of  5  month  old  Ctns−/−  mice
demonstrated a few small cells near the limbus that stained
intensively  with  phalloidin,  suggesting  the  presence  of
stromal inflammation (Figure 5B). More abundant infiltrating
cells were seen in the corneal periphery of 10 month old Ctns
−/− mice, often associated with disrupted keratocytes (Figure
5C). Both these features were more severe in 12 month old
mice, with regions of keratocyte dropout (Figure 5C, asterisk)
and decreased cell density (Figure 5D). Additionally, older
mice (12 months) showed marked changes in the corneal
endothelium,  including  loss  of  cell  uniformity
(polymegathism),  polygonality  (polymorphism)  and
increased  cell  size  with  formation  of  multinucleated  cells
(Figure 6).
To identify the presence of inflammatory cells, we stained
corneas with antibodies to CD45, a marker for bone marrow
derived cells. Cells with intense actin staining in the stroma
showed positive staining for CD45 at 7 months of age (Figure
7A).  Cells  were  located  mostly  in  the  periphery  near  the
limbus but in older Ctns−/− mice (10 months) inflammatory
infiltrates were more prominent (Figure 6B) and present in
Figure 1. Slit lamp photography of a 7
month old Ctns−/− mouse. A: The right
eye with observed crystals in the cornea
(arrows). B: The left eye of the same
mouse with end stage corneal disease.
Molecular Vision 2011; 17:2212-2220 <http://www.molvis.org/molvis/v17/a240> © 2011 Molecular Vision
2214both the peripheral and central cornea. Overall, these findings
suggest  that  cystine  crystal  deposition  leads  to  a  chronic
inflammatory  response  associated  with  loss  of  stromal
keratocytes and endothelial cells.
DISCUSSION
Using in vivo and ex vivo confocal microscopy, we have
characterized the clinical progression of corneal disease in the
Ctns−/− mouse. Our results show that cystine crystals are first
noted at 3 months in the posterior cornea, later appearing in
the anterior cornea and progressively increasing in density up
to 7 months of age. More importantly, the volume of crystals
appears to increase in quantity from 3 months to 7 month of
age,  after  which  they  begin  to  form  aggregates,  without
significant increases in crystal quantity. Increasing crystal
volume also appeared to be associated with loss of keratocyte
density and stromal inflammation from 5 to 10 months of age.
Finally, many of the eyes appear to become phthisical as early
as 7, but more commonly from 12 and 14 months of age.
Overall, our findings are similar to those of Kalatzis et al.
[36], who characterized ocular cystinosis in the Ctns−/− mouse
by slit-lamp biomicroscopy, histology and measurement of
tissue cystine levels. In this earlier report, corneal cystine
crystals were first detected by slit-lamp biomicroscopy at 3
months of age, the same time that in vivo CM detects corneal
crystals  localized  to  the  posterior  cornea.  Furthermore,
quantitative measurement of tissue cystine levels showed a 62
fold increase in corneal cystine concentration from 3 months
to  9  months  of  age.  This  was  comparable  to  the  56  fold
increase in corneal cystine crystal volume detected by in vivo
CM  in  the  current  study.  Taken  together,  these  findings
suggest that in vivo CM is as sensitive as the biochemical
measurement of tissue cystine levels in characterizing the
early progression of corneal cystinosis in the Ctns−/− mouse.
Importantly, in vivo CM is a non-invasive imaging technique
that does not require sacrificing animals or the removal and
processing  of  corneal  tissue  and  therefore  has  distinct
advantages to assessing corneal cystinosis by histology or
biochemistry. Therefore, we propose that in vivo CM may be
an  objective  and  quantitative  approach  to  assessing  the
progression of corneal cystinosis. More importantly, in vivo
CM can be performed sequentially in the same eye over time,
and can therefore be used as a sensitive approach to evaluating
the effects of conventional and novel therapeutic strategies to
Figure 2. Confocal imaging time course.
Confocal images of Ctns−/− corneas at 3
months (A), 7 months (B), 10 months
(C), and 12 months of age (D). Each
panel shows a xy (upper) and xz (lower)
slice  through  a  3-D  stack.  Cystine
crystals were identified as small, 20 µm
long,  needle-like  crystals  in  the
peripheral and central cornea. Cystine
crystals were first detected in 3 month
old  mice  (A,  arrow)  and  gradually
increased in density with age up to 7
months (B). Older Ctns−/− mice (10 and
12 month old) developed aggregates of
brightly reflecting material, presumably
cystine,  within  the  central  cornea
(arrowheads; C and D, respectively).
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2215inhibit or remove cystine crystals in the cornea. However,
future studies are required to demonstrate this capability.
It should be noted that while the cystine levels were
reported to remain stable after 9 months based on biochemical
analyses in this earlier report, overall cystine crystal volume
appeared  to  significantly  decrease  by  in  vivo  CM.  Since
decreased crystal volume was associated with a morphologic
change  in  crystal  shape  from  needle-like  to  punctate,  the
apparent decrease may be due in part to differences in the
strength of the reflected light signals from these two types of
structures.  Thus,  aggregation  of  crystals  to  form  punctate
deposits  may  give  a  low  signal,  leading  to  a  decrease  in
measured volume. Why crystals change in shape is not clear,
however,  the  loss  of  keratocytes  and  the  increased
inflammatory  cell  infiltration  suggests  that  as  cells  dies,
crystals  are  broken  up  and  perhaps  phagocytosed  by
inflammatory cells. The fact that corneal tissue cystine levels
as  measured  by  Kalatzis  et  al.  [36]  remain  stable  after  9
months, also supports the possibility that as cells die released
crystals  dissolve  into  the  extracellular  matrix,  or  are
phagocytosed and removed by wander cells.
Our observations of corneal crystal accumulation also
support the appropriateness of the Ctns−/− mouse as a model
for human cystinosis, where 50%–70% of patients share the
Figure  3.  3-D  distribution  of  crystals
within the cornea of a 7month old Ctns
−/−  mouse.  Crystal  volume  was
segmented from the 3-D in vivo CM
scan  by  thresholding  the  images  to
contain just the crystal volume.
Figure 4. Cystine crystal quantification
measured  as  the  percentage  (%)  of
crystals per stromal volume in different
age groups. We observed a progressive
increase in the crystal content in 3, 4,
and 7 month old corneas that declined in
the 10th and 12th month of age corneas
(mo=month  old;  p<0.001  in  2  month
versus  7  month,  2  month  versus  10
month,  2  month  versus  12  month,  2
month versus 4 month, 3 month versus
7 month, 3 month versus 10 month, 3
month versus 12 month, 3 month versus
4 month, 4 month versus 7 month, 4
month  versus  10  month,  12  month
versus  7  month,  10  month  versus  7
month).
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2216same  genetic  defect  [5-8].  Although  Ctns−/−  mice  did  not
receive  systemic  treatment  with  oral  cysteamine  (as  do
humans), corneal disease has been shown not to be responsive
to such systemic therapy. In cross-sectional human studies,
corneal crystals developed between birth and 6 years of age,
reaching a maximum by the mid teenage years [13,14,17,25,
42].  This  lack  of  corneal  response  to  convential  therapy
underscores the importance of evaluating novel strategies to
treat corneal cystinosis and the potential of the Ctns−/− mouse
model to identify efficacious therapies.
In human case studies, corneal crystal deposition has been
reported to start in the periphery and proceed posteriorly and
centripetally, with crystals seen in the entire corneal stroma
by age twenty [43,44]. This is in contrast to our findings where
corneal crystals were first noted in the posterior stroma, both
centrally  and  peripherally  but  proceeded  to  the  anterior
corneal with time. Our in vivo confocal images did not detect
any  crystals  in  the  corneal  endothelium  or  epithelium,  in
contrast to human confocal microscopy reports of crystals
being present in the epithelium but absent in the endothelium
[40,41].  Additionally,  our  results  showed  changes  in  the
corneal endothelium including cell loss and increased cell size
with  formation  of  multinucleated  cells  that  has  not  been
reported in any study in humans.
Thus, the Ctns−/− mouse model seems to generally track
with reported findings in humans. Finally, the findings of
inflammatory cell migration, corneal neovascularization, and
band keratopathy have also been reported in patients with
nephropathic cystinosis who are in their twenties and thirties,
again mirroring observations in the animal model [16].
In conclusion, the application of non-invasive CM, with
the  ability  to  sequentially  evaluate  and  quantify  crystal
deposition in the same cornea, opens several interesting paths
for  future  investigation.  These  include  further  studies
assessing the effects of cystine crystals on keratocyte function
and cell death. Such studies may help to elucidate molecular
and cellular mechanisms involved in other organ systems such
as the kidney and bone. In addition, in vivo CM of the Ctns−/
− mouse may be a sensitive and efficient screening tool for
alternate therapies that until now have been hampered by the
absence of an animal model. Such therapies might include
novel  drug  delivery,  gene  transfer  and  stem  cell
transplantation,  for  instance,  umbilical  mesenchymal  stem
cell [45] and human corneal stromal stem cells [46] that had
Figure 5. Corneal staining with actin and
nuclei staining. A: Actin (Green) and
nuclei (red) staining of cornea in normal
C57Bl/6  mouse  using  confocal
microscopy.  We  observed  normal
keratocytes  cell  bodies  with  dendritic
morphology  that  stained  in  the
periphery for actin. B: Actin and nuclei
staining of corneas from Ctns−/− mice at
5  months  of  age  showing  few
inflammatory  cells  (arrow).
Inflammatory cell infiltration appeared
to increase in the 10th (C, arrows) and
12th  (D,  arrows)  month  of  age  with
keratocyte dropout (asterisk).
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2217shown to be a promising treatment for congenital corneal
diseases involving keratocyte dysfunction. Importantly, novel
treatment strategies useful in the Ctns−/− mouse may have
wider  application  for  other  corneal  diseases  including
mucopolysacchridoses, corneal dystrophy, and scarring.
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